middle.news
How Pharmx’s 13% Revenue Growth Sets Up Its FY26 Ambitions
8:23pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How Pharmx’s 13% Revenue Growth Sets Up Its FY26 Ambitions
8:23pm on Friday 29th of August, 2025 AEST
Key Points
13% revenue growth to $7.53 million in FY25
Positive EBITDA of $1.61 million despite legal case costs
193% surge in Marketplace revenues year-on-year
Strong cash balance of $4.2 million at June 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pharmx Technologies (ASX:PHX)
OPEN ARTICLE